Recent Investment Analysts’ Ratings Updates for CME Group (CME)

CME Group (NASDAQ: CME) recently received a number of ratings updates from brokerages and research firms:

• 2/12/2026 – CME Group had its price target raised by Rothschild & Co Redburn from $300.00 to $333.00. They now have a “neutral” rating on the stock.
• 2/9/2026 – CME Group had its price target raised by The Goldman Sachs Group, Inc. from $264.00 to $266.00. They now have a “sell” rating on the stock.
• 2/6/2026 – CME Group had its “neutral” rating reaffirmed by UBS Group AG. They now have a $310.00 price target on the stock.
• 2/5/2026 – CME Group had its price target raised by TD Cowen from $305.00 to $328.00. They now have a “buy” rating on the stock.
• 2/5/2026 – CME Group had its price target raised by Morgan Stanley from $319.00 to $340.00. They now have an “overweight” rating on the stock.
• 2/5/2026 – CME Group had its price target raised by Barclays PLC from $304.00 to $312.00. They now have an “equal weight” rating on the stock.
• 2/5/2026 – CME Group had its price target raised by Deutsche Bank Aktiengesellschaft from $312.00 to $316.00. They now have a “buy” rating on the stock.
• 2/5/2026 – CME Group had its price target raised by JPMorgan Chase & Co. from $262.00 to $266.00. They now have an “underweight” rating on the stock.
• 2/5/2026 – CME Group had its price target raised by Royal Bank Of Canada from $295.00 to $302.00. They now have a “sector perform” rating on the stock.
• 2/4/2026 – CME Group had its price target lowered by Raymond James Financial, Inc. from $311.00 to $310.00. They now have an “outperform” rating on the stock.
• 1/22/2026 – CME Group had its price target raised by JPMorgan Chase & Co. from $256.00 to $262.00. They now have an “underweight” rating on the stock.
• 1/15/2026 – CME Group had its price target lowered by Morgan Stanley from $320.00 to $319.00. They now have an “overweight” rating on the stock.
• 1/14/2026 – CME Group was upgraded by TD Cowen from “hold” to “buy”.
• 1/14/2026 – CME Group had its price target lowered by The Goldman Sachs Group, Inc. from $265.00 to $264.00. They now have a “sell” rating on the stock.
• 1/14/2026 – CME Group was upgraded by TD Cowen from “hold” to “buy”. They now have a $305.00 price target on the stock, up from $290.00.
• 1/12/2026 – CME Group had its price target lowered by Jefferies Financial Group Inc. from $304.00 to $302.00. They now have a “buy” rating on the stock.
• 1/6/2026 – CME Group had its “neutral” rating reaffirmed by UBS Group AG.
• 1/5/2026 – CME Group had its price target raised by Raymond James Financial, Inc. from $307.00 to $311.00. They now have an “outperform” rating on the stock.
• 12/29/2025 – CME Group had its “buy (b+)” rating reaffirmed by Weiss Ratings.

CME Group Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Shareholders of record on Tuesday, March 10th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, March 10th. This is an increase from CME Group’s previous quarterly dividend of $1.25. This represents a $5.20 annualized dividend and a yield of 1.6%. CME Group’s dividend payout ratio is currently 44.80%.

Insider Transactions at CME Group

In other news, Director Martin J. Gepsman sold 300 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $305.90, for a total transaction of $91,770.00. Following the completion of the sale, the director owned 24,999 shares in the company, valued at $7,647,194.10. The trade was a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Bryan T. Durkin sold 4,200 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $309.65, for a total value of $1,300,530.00. Following the completion of the transaction, the director owned 43,007 shares in the company, valued at approximately $13,317,117.55. This represents a 8.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 30,248 shares of company stock valued at $8,355,450. Company insiders own 0.30% of the company’s stock.

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.